Nonclinical tools update: are they improving in their capabilities of predicting clinical responses?

IMMUNO-ONCOLOGY INSIGHTS

September 2022

Nonclinical tools update: are they improving in their capabilities of predicting clinical responses?

Download PDF

Foreword

To a mouse

To a mouse

Róisin McGuigan

24 September 2022

Expert Insight

Preclinical models for development of immune–oncology therapies

Preclinical models for development of immune–oncology therapies

Y Wang, S E Shelton, G Kastrunes et al.

26 September 2022

Review

Agonistic antibodies targeting 4-1BB for cancer immunotherapy

Agonistic antibodies targeting 4-1BB for cancer immunotherapy

Commentary

Translational mouse models for immuno-oncology: from syngeneic to humanized models

Translational mouse models for immuno-oncology: from syngeneic to humanized models

Stephanie C Casey

27 September 2022

Viewpoint

Harnessing components of the immune system in bioengineered 3D tumor models

Harnessing components of the immune system in bioengineered 3D tumor models

Aleksander Skardal

7 September 2022

Interview

Bispecifics come of age: how preclinical tools are helping drive translation to the clinic

Bispecifics come of age: how preclinical tools are helping drive translation to the clinic

Michelle Morrow

Webinars

Life on a chip - vascularized micro-tumor chips for mimicking clinical drug responses

Life on a chip - vascularized micro-tumor chips for mimicking clinical drug responses

Chris Hughes

Overcoming current challenges in immunotherapy drug development with patient-derived organoids

Overcoming current challenges in immunotherapy drug development with patient-derived organoids

Sylvia F Boj

Accelerating immuno-oncology innovation using humanized mouse models

Accelerating immuno-oncology innovation using humanized mouse models

Santi Suryani Chen PhD

21 September 2022